ELEUPHRAT betamethasone 0.05% (as dipropionate) lotion bottle

מדינה: אוסטרליה

שפה: אנגלית

מקור: Department of Health (Therapeutic Goods Administration)

מרכיב פעיל:

betamethasone dipropionate, Quantity: 0.64 mg/g (Equivalent: betamethasone, Qty 0.5 mg/g)

זמין מ:

ORGANON PHARMA PTY LTD

טופס פרצבטיות:

Lotion

הרכב:

Excipient Ingredients: isopropyl alcohol; purified water; sodium hydroxide; carbomer 1342

מסלול נתינה (של תרופות):

Topical

יחידות באריזה:

30mL

סוג מרשם:

(S4) Prescription Only Medicine

סממני תרפויטית:

Topical treatment of corticosteroid-responsive dermatoses. These include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. Eleuphrat Lotion is indicated wherever hair impedes access to the skin in the treatment of corticosteroid-responsive dermatoses particularly on the scalp, chest and underarms, etc. It is also indicated in the treatment of seborrhoea and psoriasis of the scalp. INDICATIONS AS AT 22 November 1995: Eleuphrat is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. These include atopic eczema, infantile eczema, nummular eczema, contact dermatitis, neurodermatitis, anogenital and senile pruritus, lichen planus, intertrigo and psoriasis. Eleuphrat Lotion is indicated wherever hair impedes access to the skin in the treatment of corticosteroid-responsive dermatoses particularly on the scalp, chest and underarms, etc. It is also

leaflet_short:

Visual Identification: Colourless, translucent, viscous lotion.; Container Type: Bottle; Container Material: LDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

מצב אישור:

Registered

תאריך אישור:

1992-09-22

מאפייני מוצר

1
AUSTRALIAN PRODUCT INFORMATION
ELEUPHRAT
® (BETAMETHASONE DIPROPIONATE)
CREAM, OINTMENT AND LOTION
1
NAME OF THE MEDICINE
Betamethasone dipropionate
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Betamethasone dipropionate equivalent to betamethasone 0.5 mg/g (0.05%
w/w).
ELEUPHRAT CREAM (0.05% w/w): Each g contains betamethasone
dipropionate equivalent to
betamethasone 0.5 mg.
ELEUPHRAT OINTMENT (0.05% w/w): Each g contains betamethasone
dipropionate equivalent to
betamethasone 0.5 mg.
ELEUPHRAT LOTION (0.05% w/w): Each mL contains betamethasone
dipropionate equivalent to
betamethasone 0.47 mg.
For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS.
3
PHARMACEUTICAL FORM
ELEUPHRAT is supplied as cream. ointment, lotion 0.05% w/w.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
ELEUPHRAT is indicated for the relief of the inflammatory and pruritic
manifestations of
corticosteroid-responsive dermatoses. These include atopic eczema,
infantile eczema, nummular
eczema, contact dermatitis, neurodermatitis, anogenital and senile
pruritus, lichen planus, intertrigo
and psoriasis.
ELEUPHRAT Lotion is indicated wherever hair impedes access to the skin
in the treatment of
corticosteroid-responsive dermatoses particularly on the scalp, chest
and underarms, etc. It is also
indicated in the treatment of seborrhoea and psoriasis of the scalp.
4.2
DOSE AND METHOD OF ADMINISTRATION
ELEUPHRAT Cream, Ointment: Apply a small amount to the affected area
twice daily. For some
patients adequate maintenance therapy may be achieved with once daily
application.
ELEUPHRAT Lotion: Apply twice daily. Part the hair with a comb, then
apply with nozzle directly
on the scalp. Squeeze bottle gently.
In most cases, 4 weeks continuous treatment should be considered the
maximum.
Children: Administration of topical corticosteroids to children should
be limited to the least amount
compatible with an effective therapeutic regimen.
4.3
CONTRAINDICATIONS
2
Hypersensitivity to betamethasone dipropionate, other corticosteroids
or any compon